Lupin Strengthens Portfolio with Acquisition of Diabetes Brands Ondero and Ondero Met from Boehringer Ingelheim

Indian pharmaceutical giant Lupin has revealed its acquisition of the diabetes brands Ondero and Ondero Met, along with their trademark rights, from Boehringer Ingelheim International GmbH.

Lupin, an Indian pharmaceutical company, has recently disclosed its acquisition of the diabetes brands Ondero and Ondero Met from Boehringer Ingelheim International GmbH.

This acquisition encompasses the associated trademark rights as well. Lupin has been actively marketing these brands within the Indian market since 2015 under a co-marketing arrangement with Boehringer Ingelheim India.

The acquisition agreement, reached in August 2022, was executed through a cash transaction amounting to ‚¬26 million.

Lupin's MD, Nilesh Gupta, stated that the company's ongoing commitment to providing high-quality pharmaceutical products to patients drives this acquisition. Adding ONDERO and ONDERO MET to Lupin's portfolio further solidifies its position as a market leader in the anti-diabetes segment.

In India, Type-2 Diabetes is a significant health concern, with an estimated 77 million individuals above 18 affected. Additionally, almost 25 million people are classified as pre-diabetic, placing them at an elevated risk of developing diabetes in the future.

Rajeev Sibal, Lupin's president for India Region Formulations, noted that diabetes is rising due to obesity and unhealthy lifestyles. He emphasised the acquisition's significance in empowering healthcare professionals to address diabetes effectively and enhance the lives of those affected by the disease.

Lupin continues its expansion streak with yet another acquisition. Following its recent growth in May 2023, when Lupin acquired French pharmaceutical company Medisol for ‚¬18 million (over Rs 160 crore), the company is now set to acquire another venture. This new acquisition involves obtaining the complete share capital of Medisol through a definitive agreement.

Lupin's strides are not limited to acquisitions alone. Its Unit-2 manufacturing facility in Mandideep, India, successfully cleared a GMP inspection by the USFDA.

Moreover, Lupin's subsidiary, Novel Laboratories Inc, headquartered in New Jersey, received the green light from the US FDA for two variations of fluocinolone acetonide oil in August 2023.